Get the Stockscreener App
1.06
0.93%
-0.01
After Hours:
1.08
0.02
+1.89%
Tscan Therapeutics Inc stock is traded at $1.06, with a volume of 879.01K.
It is down -0.93% in the last 24 hours and up +8.16% over the past month.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$1.07
Open:
$1.08
24h Volume:
879.01K
Relative Volume:
1.03
Market Cap:
$69.27M
Revenue:
$9.14M
Net Income/Loss:
$-124.31M
P/E Ratio:
-1.1073
EPS:
-0.9573
Net Cash Flow:
$-125.43M
1W Performance:
+26.19%
1M Performance:
+8.16%
6M Performance:
+3.92%
1Y Performance:
-27.89%
1-Day Range:
$1.0446
$1.12
1-Week Range:
$0.8401
$1.12
52-Week Range:
$0.8251
$2.57
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
830 WINTER STREET, WALTHAM
Compare TCRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.06 | 64.05M | 9.14M | -124.31M | -125.43M | -0.9573 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
Enterprise value to EBIT forward of TScan Therapeutics, Inc. – NASDAQ:TCRX - TradingView
TScan Therapeutics at H.C. Wainwright: phase iii push gains pace By Investing.com - Investing.com Canada
TScan Therapeutics at H.C. Wainwright: phase iii push gains pace - Investing.com
Enterprise value to revenue forward of TScan Therapeutics, Inc. – NASDAQ:TCRX - TradingView
Price to sales forward of TScan Therapeutics, Inc. – BOATS:TCRX - TradingView
Price to earnings forward of TScan Therapeutics, Inc. – BOATS:TCRX - TradingView
TScan Therapeutics, Inc. (TCRX) reports Q1 loss, lags revenue estimates - MSN
TScan Therapeutics, Inc. Actuals & Estimates (NASDAQ:TCRX) - TradingView
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewswire
H.C. Wainwright reiterates Tscan stock rating on trial data - Investing.com UK
H.C. Wainwright reiterates Tscan stock rating on trial data By Investing.com - Investing.com South Africa
TCRX Reiterated by Wedbush -- Price Target Maintained at $5.00 - GuruFocus
TCRX Reiterated by Needham -- Price Target Maintained at $6.00 - GuruFocus
A Quick Look at Today's Ratings for TScan Therapeutics(TCRX.US), With a Forecast Between $5 to $7 - Moomoo
H.C. Wainwright Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Needham Maintains TScan Therapeutics(TCRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation - Sahm
TScan reports Phase 1 data for TSC-101 blood cancer trial - grafa.com
Form 8K Tscan Therapeutics Inc For: 22 June By Investing.com - Investing.com Nigeria
TScan Therapeutics Advances TSC-101 Toward Pivotal Trial - TipRanks
TScan reports trial data for blood cancer treatment TSC-101 - Investing.com
TScan reports trial data for blood cancer treatment TSC-101 By Investing.com - Investing.com Australia
TCRX: Cohort C results support advancing TSC-101 to Phase 3, showing high efficacy and safety - TradingView
TScan Therapeutics (TCRX) shows strong TSC-101 Phase 1 data, plans pivotal trial - Stock Titan
TScan Therapeutics Announces Positive Initial Data from - GlobeNewswire
Number of shareholders of TScan Therapeutics, Inc. – NASDAQ:TCRX - TradingView
TScan Therapeutics Inc (TCRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TScan Therapeutics Inc (TCRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TScan Therapeutics Inc (TCRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TScan Therapeutics Inc (TCRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
TScan Therapeutics Inc (TCRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TScan Therapeutics Inc (TCRX) Institutional Confidence - TradingKey
TScan Therapeutics Inc (TCRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TScan Therapeutics Inc (TCRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TScan Therapeutics Inc (TCRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TScan Therapeutics (TCRX) Declines Sharply as Biotech Sector Headwinds IntensifySector Sentiment - newsline.com
Cellares and TScan to assess automated manufacturing of TSC-101 therapy - Yahoo Finance
Cellares, TScan Partner to Automate Manufacture of TCR-T Candidate - Contract Pharma
Cellares, TScan to evaluate automated manufacturing for TSC-101 By Investing.com - Investing.com Australia
Cellares, TScan to evaluate automated manufacturing for TSC-101 - Investing.com
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies - Business Wire
TCRX Q1 2026 Earnings: Wider-than-Expected Loss as Pipeline Advances Without RevenueFinancial Summary - newsline.com
TScan Therapeutics Cuts Net Loss to 28 Million Dollars - asatunews.co.id
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss - Insider Monkey
TScan Therapeutics hangs around $1.08; eyes on next week - Bez Kabli
TScan Therapeutics Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances Clinical PipelineEPS Growth Report - The Legal Advocate
TCRXTscan Therapeutics Inc Stock Price and Quote - Finviz
TScan Therapeutics (TCRX) Rallies 3.9% as Shares Test Key Resistance LevelsPercent Below MA - The Legal Advocate
TScan Therapeutics Q1 2026 Earnings: Narrowing Loss Despite EPS Miss, Stock Gains on Pipeline ProgressConsensus Forecast Report - The Legal Advocate
TScan Therapeutics Expands Authorized Shares After Stockholder Vote - The Globe and Mail
TScan Therapeutics Analyst Ratings and Price Targets | NASDAQ:TCRX - Benzinga
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):